

10/660,908

-2-

PC25095A

Amendments to the Claims:

Claims 1-7 (Canceled)

8. (Original) A compound or salt that is selected from the following compounds and their pharmaceutically acceptable salts:

6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-4-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-4S-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-4R-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-1,4-dimethyl-3,4-dihydro-1H-quinolin-2-one;

6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one;

6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-1,4,4-trimethyl-3,4-dihydro-1H-quinolin-2-one;

6-[2-(4-benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one;

6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-3-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one;

6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-3,4-dimethyl-3,4-dihydro-1H-quinolin-2-one;

6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-1,3,3,4,4-pentamethyl-3,4-dihydro-1H-quinolin-2-one;

10/660,908

-3-

PC25095A

6-[2-(4-benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-3,3,4-trimethyl-3,4-dihydro-1H-quinolin-2-one;

6-{2-[4-(1H-indazol-3-yl)-piperazin-1-yl]-ethyl}-4-methyl-3,4-dihydro-1H-quinolin-2-one;

6-{2-[4-(1H-indazol-3-yl)-piperazin-1-yl]-ethyl}-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one;

6-{2-[4-(1H-indazol-3-yl)-piperazin-1-yl]-ethyl}-3-methyl-3,4-dihydro-1H-quinolin-2-one;

6-{2-[4-(1H-indazol-3-yl)-piperazin-1-yl]-ethyl}-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one;

6-{2-[4-(1H-indazol-3-yl)-piperazin-1-yl]-ethyl}-3,4-dimethyl-3,4-dihydro-1H-quinolin-2-one;

6-[2-(4-benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-1,3,3,4,4-pentamethyl-3,4-dihydro-1H-quinolin-2-one;

6-[2-(4-benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3,4-trimethyl-3,4-dihydro-1H-quinolin-2-one;

6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one, mesylate salt;

6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one methanesulfonate;

6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-fluoro-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one hydrochloride;

6-{3-[4-(1H-indazol-3-yl)-piperazin-1-yl]-propyl}-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one;

7-chloro-6-[3-(4-1,2-benzisothiazol-3-yl-piperazin-1-yl)-propyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one;

7-chloro-6-[3-(4-1,2-benzisoxazol-3-yl-piperazin-1-yl)-propyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one;

6-[3-(4-1,2-benzisothiazol-3-yl-piperazin-1-yl)-propyl]-4-methyl-3,4-dihydro-1H-quinolin-2-one;

10/660,908

-4-

PC25095A

6-[3-(4-1,2-benzisoxazol-3-yl-piperazin-1-yl)-propyl]-4-methyl-3,4-dihydro-1H-quinolin-2 one;

6-{3-[4-(1H-indazol-3-yl)-piperazin-1-yl]-propyl}-4-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[3-(4-1,2-benzisothiazol-3-yl-piperazin-1-yl)-propyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one;

6-[3-(4-1,2-benzisoxazol-3-yl-piperazin-1-yl)-propyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one;

6-{3-[4-(1H-indazol-3-yl)-piperazin-1-yl]-propyl}-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one;

6-[3-(4-1,2-benzisothiazol-3-yl-piperazin-1-yl)-propyl]-3-methyl-3,4-dihydro-1H-quinolin-2-one; and

6-{3-[4-(1H-indazol-3-yl)-piperazin-1-yl]-propyl}-3-methyl-3,4-dihydro-1H-quinolin-2-one.

Claims 9-12 (Canceled)

13. (Currently amended) A pharmaceutical composition for treating a disorder or condition selected from single episodic or recurrent major depressive disorders, dysthymic disorders, depressive neurosis and neurotic depression, melancholic depression including anorexia, weight loss, insomnia, early morning waking or psychomotor retardation, atypical depression (or reactive depression) including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affective disorder and pediatric depression; bipolar disorders or manic depression, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; conduct disorder, disruptive behavior disorder, attention deficit hyperactivity disorder (ADHD), behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder; anxiety disorders such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social

10/660,908

-5-

PC25095A

anxiety, social phobia, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalized anxiety disorders; borderline personality disorder; schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders brief psychotic disorders, shared psychotic disorders, psychotic disorders with delusions or hallucinations, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder; mood disorders associated with schizophrenia; delirium, dementia, and amnesia and other cognitive or neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorders, loss of executive function, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple etiologies; movement disorders such as akinesias, dyskinesias, including familial paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome; extra-pyramidal movement disorders such as medication induced movement disorders, for example, neuroleptic induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic induced acute dystonia, neuroleptic induced acute akathisia, neuroleptic induced tardive dyskinesia and medication induced postural tremor; chemical dependencies and addictions (e.g., dependencies on, or addictions to, alcohol, heroin, cocaine, benzodiazepines, nicotine, or phenobarbital) and behavioral addictions such as an addiction to gambling; and ocular disorders such as glaucoma and ischemic retinopathy in a mammal, including a human, comprising an amount of a compound according to claim 149, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition, and a pharmaceutically acceptable carrier.

14. (Withdrawn) A method for treating a disorder or condition selected from bipolar disorders or mania depression, for example, bipolar I disorder, and bipolar II disorder, or schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders brief psychotic disorders, shared psychotic

BEST AVAILABLE COPY

10/660,908

-6-

PC25095A

disorders, psychotic disorders with delusions or hallucinations, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder, mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder, mood disorders associated with schizophrenia, delirium, dementia, and amnesia and other cognitive or neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorders, loss of executive function, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt Jakob disease, or due to multiple etiologies; movement disorders such as akinesias, dyskinesias, including familial paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALVSYS and akinetic rigid syndrome; extra-pyramidal movement disorders such as medication induced movement disorders, for example, neuroleptic induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic induced acute dystonia, neuroleptic induced acute akathisia, neuroleptic induced tardive dyskinesia and medication induced postural tremor; chemical dependencies and addictions (e.g., dependencies on, or addictions to, alcohol, heroin, cocaine, benzodiazepines, nicotine, or phenobarbital) and behavioral addictions such as an addiction to gambling; and ocular disorders such as glaucoma and ischemic retinopathy in a mammal, including a human, comprising administering to a the mammal in need of such treatment an amount of a compound according to claim 149, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition.

15. (Withdrawn) A method according to claim 14, wherein the disorder or condition that is being treated is selected from major depression, single episode depression, recurrent depression, child abuse induced depression, postpartum depression, dysthymia, cyclothymia and bipolar disorder.

16. (Withdrawn) A method according to claim 14, wherein the disorder or condition that is being treated is selected from schizophrenia, schizoaffective disorder, delusional disorder,

10/660,908

-7-

PC25095A

~~substance-induced psychotic disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, and schizophreniform disorder.~~

Claim 17-30 (Canceled)

31. (Currently amended) A pharmaceutical composition for treating a disorder or condition selected from single episode or recurrent major depressive disorders, dysthymic disorders, depressive neurosis and neurotic depression, melancholic depression including anorexia, weight loss, insomnia, early morning waking or psychomotor retardation; atypical depression (or reactive depression) including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affective disorder and pediatric depression; bipolar disorders or manic depression, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; conduct disorder; disruptive behavior disorder; attention deficit hyperactivity disorder (ADHD); behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder; anxiety disorders such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social anxiety, social phobia, obsessive compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalized anxiety disorders; borderline personality disorder; schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders brief psychotic disorders, shared psychotic disorders, psychotic disorders with delusions or hallucinations, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder; mood disorders associated with schizophrenia; delirium, dementia, and amnesia and other cognitive or neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorders, loss of executive function, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple etiologies; movement disorders such as akinesia, dyskinesia, including

10/660,908

-8-

PC25095A

familial paroxysmal dyskinetic spasmodicities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic rigid syndrome; extra pyramidal movement disorders such as medication induced movement disorders, for example, neuroleptic induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic induced acute dystonia, neuroleptic induced acute akathisia, neuroleptic induced tardive dyskinesia and medication induced postural tremor; chemical dependencies and addictions (e.g., dependencies on, or addictions to, alcohol, heroin, cocaine, benzodiazepines, nicotine, or phenobarbital) and behavioral addictions such as an addiction to gambling; and ocular disorders such as glaucoma and ischemic retinopathy in a mammal, including a human, comprising an amount of a compound according to claim 850, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition, and a pharmaceutically acceptable carrier.

Claim 32-48 (Canceled)

49. (New) A compound which is 6-[2-(4-benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-8-chloro-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one and pharmaceutically acceptable salts thereof.

50. (New) A compound which is 6-[2-(4-benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-8-chloro-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one hydrochloride.